Patient-reported awareness and value of multi-cancer early detection tests.

360 Background: Multi-cancer early detection (MCED) tests have the potential to detect multiple types of cancer; they do not diagnose cancer but can signal that additional workup is necessary. None are approved by the FDA and, due to poor insurance coverage, they may lead to significant costs for patients. This study examines patient-reported awareness and perceived value of MCED tests by survivorship status. Methods: Nationally representative data from the 2024 Health Information National Trends Survey were used. Demographic variables included: age, race, ethnicity, occupation, marital status, education, and income. Those with a prior cancer diagnosis (survivors) were compared to those without (w/o) cancer. Univariate and multivariate logistic regression analyses (MVA) focused on predictors of MCED tests awareness and assigned value (not at all/a little vs somewhat/very valuable). Results: Overall, 6746 were included of which 1073 (15.9%) were cancer survivors. Survivors were older (median 70 vs 55), more commonly female (44.2% vs 38.8%), White race (80.7% vs 72.6%), and married (49.2% vs 44.3%), they were less often working full-time (29.7% vs. 72.6%) than those w/o a cancer history (p < 0.05 for all). Most had not heard of MCED. Survivors were more likely to have heard of MCED (19.4% vs. 16.7%), as were those identified as female (18.8% vs 15.9%), Hispanic (20.1% vs 16.4%), and currently employed (18.2% vs 15.9%) (p < 0.05 for all). MVA showed certain demographic groups were associated with knowledge of MCED including male sex [OR: 0.81, 95% CI 0.71 - 0.93, p = 0.003], non-Hispanic ethnicity [OR: 0.77, 95% CI 0.65 - 0.91, p = 0.003], and employed status [OR: 1.17, 95% CI 1.02 - 1.35, p = 0.029]. Most did not value MCED tests. The groups that associated slightly higher value were those younger (median age 57 vs 59), white race (25.9% vs 23.1%), non-Hispanic ethnicity (26.1% vs. 20.7%), non-married/other (26.6% vs 23.2%), high school education or less (27.1% vs. 24.2%), not employed (26.4% vs. 23.9%), and < 50K annual household income (27.6% vs. 22.7%) (p < 0.05 for all). MVA showed certain demographic groups were associated with valuing MCED tests including younger age [OR: 1.01, 95% CI 1.01 - 1.02, p < 0.001], white race [OR: 1.38, 95% CI 1.19 - 1.60, p < 0.001], non-Hispanic ethnicity [OR: 1.65, 95% CI 1.39 - 1.60, p < 0.001], employed status [OR: 0.83, 95% CI 0.72 - 0.96, p = 0.012], and lower income [OR: 1.39, 95% CI 1.22 - 1.58, p < 0.001]. Conclusions: In this national study, participants reported low levels of knowledge of MCED tests and low perceived value; perhaps commensurate with MCED’s current status as an unapproved test with unclear evidence-based role in oncology. After controlling for demographic differences, survivors were no more likely to have heard of, or value, MCED tests. While future research is needed to clarify how these tests will be best applied, communication and education with patients is needed as well.